Viking Therapeutics Inc expected to post a loss of $1.25 a share - Earnings Preview

Viking Therapeutics

27/07/2026 21:36

Viking Therapeutics Inc VKTX.OQ VKTX.O is expected to  show no change in quarterly revenue when it reports  results on July 29 for the period ending June 30 2026

​LSEG's mean analyst estimate for Viking Therapeutics Inc is for a loss of $1.25 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Viking Therapeutics Inc is $97.50, about 180.3% above its last closing price of $34.79
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.08
-1.01
-1.37
Missed
-35.1
Dec. 31 2026
-0.93
-0.89
-1.38
Missed
-54.3
Sep. 30 2025
-0.70
-0.68
-0.81
Missed
-19.6​
Jun. 30 2025
-0.46
-0.45
-0.58
Missed
-29.9
​​Mar. 31 2025
-0.32
-0.32
-0.41
Missed
-26.4
Dec. 31 2024
-0.25
-0.28
-0.32
Missed
-16​
Sep. 30 2024
-0.23
-0.25
-0.22
Beat
12.6
Jun. 30 2024
-0.28
-0.27
-0.20
Beat
25.9
This summary was machine generated July 27 at 20:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)